Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
17 Apr 2023 07:00 AM
RNS
AVA3996 data poster presented at AACR
06 Apr 2023 07:00 AM
RNS
1st US Clinical Investigator AVA6000 Sites Opened
05 Apr 2023 07:00 AM
RNS
First Patient Dosed in Fifth Cohort of AVA6000
03 Apr 2023 07:00 AM
RNS
Notice of Results and Investor Presentation
27 Mar 2023 07:00 AM
RNS
AVA3996 data poster presentation at AACR
13 Mar 2023 07:00 AM
RNS
Statement re: Silicon Valley Bank
23 Feb 2023 07:00 AM
RNS
Avacta Therapeutics Division Science Day
13 Feb 2023 07:00 AM
RNS
Issue of Equity and Total Voting Rights
23 Jan 2023 12:20 PM
RNS
Issue of Equity and Total Voting Rights
17 Jan 2023 02:05 PM
RNS
Second Price Monitoring Extn
17 Jan 2023 02:00 PM
RNS
Price Monitoring Extension
17 Jan 2023 11:05 AM
RNS
Second Price Monitoring Extn
17 Jan 2023 11:00 AM
RNS
Price Monitoring Extension
17 Jan 2023 09:05 AM
RNS
Second Price Monitoring Extn
17 Jan 2023 09:00 AM
RNS
Price Monitoring Extension
17 Jan 2023 07:00 AM
RNS
Successful Completion of Fourth Dose Escalation
16 Jan 2023 10:15 AM
RNS
Block Listing Application to AIM
19 Dec 2022 07:00 AM
RNS
Avacta to Host Therapeutics Division Science Day
08 Nov 2022 07:01 AM
RNS
Director/PDMR Shareholding
08 Nov 2022 07:00 AM
RNS
Result of the Open Offer
31 Oct 2022 01:32 PM
RNS
Avacta to Present at Theranostics FAP Summit
31 Oct 2022 11:05 AM
RNS
Second Price Monitoring Extn
31 Oct 2022 11:00 AM
RNS
Price Monitoring Extension
28 Oct 2022 07:00 AM
RNS
Block Listing Six Monthly Return
20 Oct 2022 08:01 AM
RNS
Director/PDMR Shareholding
20 Oct 2022 08:01 AM
RNS
Admission of the Company's Ordinary Shares
20 Oct 2022 07:00 AM
RNS
Posting of the Company's Open Offer Circular
18 Oct 2022 11:49 AM
RNS
Result of Placing
18 Oct 2022 09:16 AM
RNS
Private CB and ABB Launch
18 Oct 2022 09:14 AM
RNS
Proposed acquisition of Launch Diagnostics
29 Sep 2022 07:00 AM
RNS
Interim Results for the Period Ended 30 June 2022
26 Sep 2022 07:00 AM
RNS
Notice of Results
05 Sep 2022 07:00 AM
RNS
AVA6000 receives Orphan Drug Designation from FDA
01 Sep 2022 07:00 AM
RNS
Phase I study of AVA6000 advances to fourth cohort
21 Jul 2022 07:00 AM
RNS
AffyXell successfully completes funding round
30 Jun 2022 07:00 AM
RNS
LG Chem renews license triggers payment to Avacta
29 Jun 2022 09:05 AM
RNS
Second Price Monitoring Extn
29 Jun 2022 09:00 AM
RNS
Price Monitoring Extension
29 Jun 2022 07:00 AM
RNS
Second dose escalation in phase 1 trial of AVA6000
23 Jun 2022 04:41 PM
RNS
Second Price Monitoring Extn
23 Jun 2022 04:36 PM
RNS
Price Monitoring Extension
23 Jun 2022 04:27 PM
RNS
Result of Annual General Meeting
16 Jun 2022 04:41 PM
RNS
Second Price Monitoring Extn
16 Jun 2022 04:36 PM
RNS
Price Monitoring Extension
31 May 2022 07:00 AM
RNS
Posting of Annual Report and Notice of AGM
16 May 2022 12:00 PM
RNS
AffyXell expands partnership with GenScript ProBio
11 May 2022 07:00 AM
RNS
London Therapeutics headquarters established
06 May 2022 07:00 AM
RNS
Block Listing Application to AIM (update)
28 Apr 2022 01:53 PM
RNS
Block Listing Application to AIM
14 Apr 2022 05:01 PM
RNS
Issue of Equity and Total Voting Rights
UK 100